Posts tagged John Newman


This Analyst Sees 1035% Upside for Palatin Technologies, Inc. (PTN) Following New Deal with Fosun Pharma

PTN focusing on entering the EU market through partnerships, says analyst.

Read more

Synergy Pharmaceuticals Inc (SGYP) Has Encouraging Sustainability Through 2019 Thanks to $300 Million Debt Financing

Synergy protects “financial health” without the sacrifice of extra pressure on share price, says Canaccord.

Read more

Kite Pharma Inc (KITE): FDA Approval of Kymriah Is Good News for the Future of Axi-cel

Canaccord Positive on Safety Profile of Kite’s Axi-Cel

Read more

Synergy Pharmaceuticals Inc (SGYP) Trulance Market Adoption Pattern Looks Positive: Canaccord

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) stock is on the downward spiral today, to the harsh, discordant …

Read more

Synergy Pharmaceuticals Inc (SGYP) Trulance Poses Enticing Long-Term Uptake

Second quarter earnings for the year are due sometime around mid-August from Synergy Pharmaceuticals Inc …

Read more

Aurinia Pharmaceuticals Inc (AUPH): Voclosporin’s Long-Term Phase 2 Data Points for Assessing the Probability of Phase 3 Success

This is an exciting time for Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) and its shareholders. The shares have …

Read more

Canaccord Chimes in on Synergy Pharmaceuticals Inc (SGYP) as It Prepares for Trulance Launch

Yesterday, Synergy Pharmaceuticals Inc (NASDAQ:SGYP) reported fourth-quarter financial results and reiterated the launch of Trulance (plecanatide), …

Read more

Canaccord Applauds Aurinia Pharmaceuticals Inc (AUPH) As Shares Shatter Through the Roof at 66%

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is on fire today with shares zooming up 66% in pre-market …

Read more

Synergy Pharmaceuticals Inc: Canaccord’s Take on Linzess Approval

Synergy Pharmaceuticals Inc’s (NASDAQ:SGYP) constipation drug Trulance will compete directly with Ironwood Pharmaceuticals (NASDAQ:IRWD) and Allergan‘s …

Read more

Canaccord Positive On Synergy Pharmaceuticals Inc’s (SGYP); Skeptical On Competitor’s Drug Ahead Of FDA Approval Decision

Canaccord analyst John Newman weighs in on Synergy Pharmaceuticals Inc (NASDAQ:SGYP), as competitor Ironwood Pharmaceuticals (NASDAQ:IRWD) has …

Read more